{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:35:18Z","timestamp":1773405318382,"version":"3.50.1"},"reference-count":24,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1507\/endocrj.ej17-0368","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T22:11:37Z","timestamp":1511907097000},"page":"253-260","source":"Crossref","is-referenced-by-count":6,"title":["Paraganglioma as a risk factor for bone metastasis"],"prefix":"10.1507","volume":"65","author":[{"given":"Maki","family":"Yokomoto-Umakoshi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Umakoshi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Tsuiki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaho","family":"Hamanaka\u2011Hiroshima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tagami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhide","family":"Naruse","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Zarnegar R, Kebebew E, Duh QY, Clark OH (2006) Malignant pheochromocytoma. Surg Oncol Clin N Am 15: 555\u2013571.","DOI":"10.1016\/j.soc.2006.05.009"},{"key":"2","unstructured":"2 Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, <i>et al.<\/i> (2016) European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a pheochromocytoma or a paraganglioma. Eur J Endocrinol 174: G1\u2013G10."},{"key":"3","unstructured":"3 Naruse M &amp; PHEO-J Group. Nation-wide survey and PHEO network for the study of pheochromocytoma\/paraganglioma in Japan (PHEO-J) (2011) <i>Endocrine Reviews<\/i>. 32 Meeting Abstracts: 2\u2013631. The Endocrine Society\u2019s 93<sup>rd<\/sup> annual meeting &amp; expo, abstract No. P2\u2013631."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Abdel-Aziz TE, Prete F, Conway G, Gaze M, Bomanji J, et al. (2015) Pheochromocytomas and paragangliomas: a difference in disease behaviour and clinical outcomes. J Surg Oncol 112: 486\u2013491.","DOI":"10.1002\/jso.24030"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Choi YM, Sung TY, Kim WG, Lee JJ, Ryu JS, et al. (2015) Clinical course and prognostic factors in patients with malignant pheochromocutoma and paraganglioma: a single institution experience. J Surg Oncol 112: 815\u2013821.","DOI":"10.1002\/jso.24063"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, et al. (2014) Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 99: 1915\u20131942.","DOI":"10.1210\/jc.2014-1498"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, et al. (2008) Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 15: 311\u2013323.","DOI":"10.1677\/ERC-07-0217"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, et al. (2013) Bone metastasis and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98: 1492\u20131497.","DOI":"10.1210\/jc.2012-4231"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Coleman RE (2006) Clinical features of metastatic bone metastases and risk of skeletal morbidity. Clin Cancer Res 12: 6243s\u20136249s.","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Suva LJ, Griffin RJ, Makhoul I (2009) Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 16: 703\u2013713.","DOI":"10.1677\/ERC-09-0012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, et al. (2016) Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases. Tumor Biol 37: 1131\u20131140.","DOI":"10.1007\/s13277-015-3907-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Lipton A, Cook R, Brown J, Body JJ, Smith M, et al. (2013) Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clin Oncol (R Coll Radiol) 25: 217\u2013226.","DOI":"10.1016\/j.clon.2012.11.004"},{"key":"13","unstructured":"13 Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, et al. (1999) Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mol Pathol 12: 1107\u20131111."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, et al. (2014) Pathological grading for predicting metastasis in paeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405\u2013414.","DOI":"10.1530\/ERC-13-0494"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, et al. (2017) Effect of longer-interval <i>vs.<\/i> standard dosing of zolendronic acid on skeletal events in patients with bone metastases a randomized clinical trial. JAMA 317: 48\u201358.","DOI":"10.1001\/jama.2016.19425"},{"key":"16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-8674(02)01049-8","volume":"111","author":"S Takeda","year":"2002","unstructured":"17 Takeda S, Elefteriou F, Levasscur R, Liu X, Zhao L, et al. (2002) Leptin regulates bone formation <i>via<\/i> the sympathetic nervous system. Cell 111: 305\u2013317.","journal-title":"Cell","ISSN":"https:\/\/id.crossref.org\/issn\/0092-8674","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18 Veldhuis-Vlug AG, EI Mahdiui M, Endert E, Heijboer AC, Fliers E, et al. (2012) Bone resorption is increased in pheochromocytoma patients and normalizes following adrenalectomy. J Clin Endocrinol Metab 97: E2093\u2013E2097.","DOI":"10.1210\/jc.2012-2823"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19 Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, et al. (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96: 717\u2013725.","DOI":"10.1210\/jc.2010-1946"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Galan SR, Kann PH (2013) Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrionol (Oxf) 78: 169\u2013175.","DOI":"10.1111\/cen.12071"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21 Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, et al. (2005) A HIF1\u03b1 regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLOS Genet 1: 72\u201380.","DOI":"10.1371\/journal.pgen.0010008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22 Wu B, Wang L, Yang X, Mao M, Ye C, et al. (2016) Norepinephrine inhibits mesenchymal stem cell chemotaxis migration by increasing stromal cell-derived factor-1 secretion by vascular endothelial cells <i>via<\/i> NE\/abrd3\/JNK pathway. Exp Cell Res 349: 214\u2013220.","DOI":"10.1016\/j.yexcr.2016.09.007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23 Di Martino A, Caldaria A, De Vivo V, Denaro V (2016) Metastatic epidural spinal cord compression. Expert Rev Anticancer Ther 16: 1189\u20131198.","DOI":"10.1080\/14737140.2016.1240038"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24 Georgy BA (2008) Metastatic spinal lesions: state-of-the-art treatment options and future trends. AJNR Am J Neuroradiol 29: 1605\u20131611.","DOI":"10.3174\/ajnr.A1137"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71: 80\u201394.","DOI":"10.1016\/j.ejca.2016.10.021"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/3\/65_EJ17-0368\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T01:38:18Z","timestamp":1570412298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/3\/65_EJ17-0368\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej17-0368","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}